Nanogen: Doppelte Bodenbildung.....!!! - 500 Beiträge pro Seite (Seite 2)
eröffnet am 29.06.06 23:27:17 von
neuester Beitrag 24.09.09 14:33:18 von
neuester Beitrag 24.09.09 14:33:18 von
Beiträge: 540
ID: 1.068.707
ID: 1.068.707
Aufrufe heute: 0
Gesamt: 66.590
Gesamt: 66.590
Aktive User: 0
ISIN: US6300751095 · WKN: 911841
Werte aus der Branche Nanotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5095 | +11,73 | |
| 2,5400 | +3,04 | |
| 4,5800 | +0,88 | |
| 2,7200 | +0,18 | |
| 0,5100 | 0,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 72,75 | -3,64 | |
| 159,50 | -4,78 | |
| 31,20 | -5,02 | |
| 1,0425 | -5,23 | |
| 0,9700 | -6,73 |
Feedback
Antwort auf Beitrag Nr.: 35.726.259 von kardoss12 am 28.10.08 10:15:36
Schaut so aus, als ob Dein Zeitpunkt käme.
Vergiss aber um Gottes Willen den uralten und
schon so oft strapazierten Grundsatz nicht:
[b]"NEVER CATCH A FALLING BLADE !"[/b]
Glaub mir, ich weiss wovon ich gerade bei diesem Titel poste.
dg.
Schaut so aus, als ob Dein Zeitpunkt käme.
Vergiss aber um Gottes Willen den uralten und
schon so oft strapazierten Grundsatz nicht:
[b]"NEVER CATCH A FALLING BLADE !"[/b]
Glaub mir, ich weiss wovon ich gerade bei diesem Titel poste.
dg.
...ja deshalb habe ich gerade gleich 20000 stk gekauft!
"Fallendes Messer"!
Der Chart sieht auch danach aus!
"Fallendes Messer"!
Der Chart sieht auch danach aus!
Antwort auf Beitrag Nr.: 36.086.780 von Marion29 am 27.11.08 09:24:23
Hab ich jetzt nicht ganz verstanden !
Hast Dir jetzt blutige Finger geholt oder nicht ?*
Wann haste denn geordert ?
*Bei mir warens nicht nur die Finger !
Liebe Grüsse
dg:
Hab ich jetzt nicht ganz verstanden !
Hast Dir jetzt blutige Finger geholt oder nicht ?*
Wann haste denn geordert ?
*Bei mir warens nicht nur die Finger !
Liebe Grüsse
dg:
Moin moin dg,
ja ich hatte da gerade zu 0,145 gekauft, also so blutig sind die Finger nicht!
Ich bleib bei Nanog!
LG
ML
ja ich hatte da gerade zu 0,145 gekauft, also so blutig sind die Finger nicht!
Ich bleib bei Nanog!
LG
ML
Antwort auf Beitrag Nr.: 36.128.368 von Marion29 am 02.12.08 08:40:58
Dann bist wenigstens nicht in solch einer Blutlache wie ich !
Gib nur
1.: Obacht
2.: nochmals Obacht
und
3.: Obacht,
denn so derartig volatil wie NGEN sich verhält,
kanns auch nochmals ordentlich bumms machen - erwarte ich sogar !
Lass weiter sporadisch von Dir hören, scheint so wenn wir noch die
beiden "Resteverwerter" wären.
Liebe Grüsse
dg.
Dann bist wenigstens nicht in solch einer Blutlache wie ich !
Gib nur
1.: Obacht
2.: nochmals Obacht
und
3.: Obacht,
denn so derartig volatil wie NGEN sich verhält,
kanns auch nochmals ordentlich bumms machen - erwarte ich sogar !
Lass weiter sporadisch von Dir hören, scheint so wenn wir noch die
beiden "Resteverwerter" wären.
Liebe Grüsse
dg.
Trading Spotlight
Ich denke der Boden ist bei NGN gefunden, in D wird ja nicht viel gehandelt, deshalb diese extremen Schwankungen.
Wenn ich mir US anschaue handeln die aber auch nicht mehr an einem Tag wie ich NGN-Aktien im Depot habe.
"Resteverwertung" machen wir hoffentlich nicht!
Die NGN hat in der Vergangenheit oft enttäuscht, deshalb wundert mich der schlechte Kursverlauf nicht.
Eigentlich wollten die schon lange mit Profit arbeiten!
Wenn die den Reverse-Split endlich bekannt geben, dann gehts wieder nach Norden!
LG
ML
Wenn ich mir US anschaue handeln die aber auch nicht mehr an einem Tag wie ich NGN-Aktien im Depot habe.
"Resteverwertung" machen wir hoffentlich nicht!
Die NGN hat in der Vergangenheit oft enttäuscht, deshalb wundert mich der schlechte Kursverlauf nicht.
Eigentlich wollten die schon lange mit Profit arbeiten!
Wenn die den Reverse-Split endlich bekannt geben, dann gehts wieder nach Norden!
LG
ML
Gibts uns noch oder landen wir jetzt doch bei
den rosa Zettelchen an der OTC ?
Hat irgendjemand News von Nanogen ?
Liebe Grüsse
dg.
Antwort auf Beitrag Nr.: 36.086.780 von Marion29 am 27.11.08 09:24:23Hi Marion29,
ich denke mal das dongabor recht hat.
Niemals ins fallende Messer kaufen. Hatte früher auch öffter mal derartige Aktionen getätigt und bin kräftig auf die Nase gefallen.
Nanogen hatte ich auch mal bei 36ct gekauft. Ich hab sie immer noch.
Der Kurs fällt seitdem.
Ein sicheres Indiz das Aktienkurse fallen sind die sogenannten pushermails. Ich will hier mal keine Namen nennen.
Das Prinzip ist immer das gleiche.
Es geht oft darum den neulingen an der Börse das Geld aus der Tasche zu ziehen.
Meiner Meinung kann man Nanogen erst mal wieder kaufen wenn ein deutlicher Aufwärtstrend zu erkennen ist. Ich gebe zu den ganzen Thread hab ich nicht gelesen und den aktuellen Kurs kenne ich auch nicht. Aber solange kein Aufwärtstrend zu erkennen ist würde ich nicht kaufen.
thomas
ich denke mal das dongabor recht hat.
Niemals ins fallende Messer kaufen. Hatte früher auch öffter mal derartige Aktionen getätigt und bin kräftig auf die Nase gefallen.
Nanogen hatte ich auch mal bei 36ct gekauft. Ich hab sie immer noch.
Der Kurs fällt seitdem.
Ein sicheres Indiz das Aktienkurse fallen sind die sogenannten pushermails. Ich will hier mal keine Namen nennen.
Das Prinzip ist immer das gleiche.
Es geht oft darum den neulingen an der Börse das Geld aus der Tasche zu ziehen.
Meiner Meinung kann man Nanogen erst mal wieder kaufen wenn ein deutlicher Aufwärtstrend zu erkennen ist. Ich gebe zu den ganzen Thread hab ich nicht gelesen und den aktuellen Kurs kenne ich auch nicht. Aber solange kein Aufwärtstrend zu erkennen ist würde ich nicht kaufen.
thomas
Antwort auf Beitrag Nr.: 36.093.659 von dongabor am 27.11.08 17:32:40Hi Dongabor,
schau mal auf ihr Profil wie lange sie schon hier bei WO angemeldet ist.
Die Kaufentscheiung ins fallende Messer zu kaufen ist ein typischer Anfängerfehler. Das hab ich auch sehr oft gemacht.
Ich musste dafür teuer bezahlen.
thomas
schau mal auf ihr Profil wie lange sie schon hier bei WO angemeldet ist.
Die Kaufentscheiung ins fallende Messer zu kaufen ist ein typischer Anfängerfehler. Das hab ich auch sehr oft gemacht.
Ich musste dafür teuer bezahlen.
thomas
vielleich kommen sie ja endlich in die Gewinnzone? Umsatz von 5 mille in 2004 bis auf 50 mill in 2008 gesteigert!
Und der Grippeschnelltest könnte zu noch mehr Wachstum beitragen?
Click here for more details on the Nanogen merger with The Elitech Group. HX Diagnostics and Nanogen Expand Collaboration
Aug 5, 2008
EMERYVILLE, Calif. – August 5, 2008 – HX Diagnostics, Inc. announced today that it has expanded its license and development agreement with Nanogen, Inc. (Nasdaq: NGEN) to include the development of additional rapid, point-of-care diagnostics for respiratory infectious diseases. As part of the three-year agreement, the companies will employ the same underlying technology used in their previously announced joint project, a diagnostic for the differential diagnosis of seasonal and pandemic influenza.
The companies are currently in the final stages of development on a highly sensitive diagnostic assay that can simultaneously detect multiple strains and subtypes of influenza, including avian influenza, with one simple and rapid test. The fluID™ Rapid Influenza Test is an easy-to-use, low cost device utilizing high affinity monoclonal antibodies and proprietary lateral flow technology from Nanogen. The technology is capable of detecting and differentiating multiple analytes in the sample. In pre-clinical trials, the assay demonstrated greater than 2 logs improvement in sensitivity over currently available assays.
The same proprietary lateral flow technology and device design will be used in the newly announced development programs. Once development is complete, HX Diagnostics will be granted exclusive commercial license to manufacture and market the resulting products upon regulatory approval.
“The expanded agreement with Nanogen gives us the opportunity to open up our potential market by providing full panels of diagnostics for respiratory illnesses,” said Wendy Benson, president and chief executive officer of HX Diagnostics. “The rapid, accurate diagnosis of these infectious diseases will enable quicker treatment and recovery times for patients.”
The development of the fluID test is supported in part by a 2006 grant from the U.S. Centers for Disease Control and Prevention as part of the U.S. government’s efforts to strengthen its readiness for a potential influenza pandemic.
”Our R&D efforts on the CDC/HX avian influenza project have resulted in a next generation rapid diagnostic technology with breakthrough improvements in sensitivity and precision,” said David Ludvigson, Nanogen’s president and chief operating officer. “Expanding our relationship with HX Diagnostics to include additional respiratory disease diagnostics is a good way for Nanogen to leverage the technology and fulfill our mission of enabling better patient care by bringing to market easier and faster diagnostics.”
About HX Diagnostics, Inc.
HX Diagnostics was founded in 2006 as part of the Kleiner Perkins Caufield & Byers Pandemic Preparedness and BioDefense Initiative with a mission to create improved diagnostics for emerging and infectious diseases. Through its collaborations with leading institutions around the world, HX Diagnostics is creating a diagnostic testing platform that can easily be tailored to enable rapid updates to the device kit as new strains of seasonal or potentially pandemic disease emerge. For more information please visit www.hxdiagnostics.com.
About Nanogen, Inc.
Nanogen, Inc., develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company's products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen's website at www.nanogen.com.
Institutionelle gehen auch langsam wieder mit kleinen Positionen rein!
http://www.mffais.com/ngen.html
habe mir gestern ne kleine Startposition zugelegt!
gruss Macos
Und der Grippeschnelltest könnte zu noch mehr Wachstum beitragen?
Click here for more details on the Nanogen merger with The Elitech Group. HX Diagnostics and Nanogen Expand Collaboration
Aug 5, 2008
EMERYVILLE, Calif. – August 5, 2008 – HX Diagnostics, Inc. announced today that it has expanded its license and development agreement with Nanogen, Inc. (Nasdaq: NGEN) to include the development of additional rapid, point-of-care diagnostics for respiratory infectious diseases. As part of the three-year agreement, the companies will employ the same underlying technology used in their previously announced joint project, a diagnostic for the differential diagnosis of seasonal and pandemic influenza.
The companies are currently in the final stages of development on a highly sensitive diagnostic assay that can simultaneously detect multiple strains and subtypes of influenza, including avian influenza, with one simple and rapid test. The fluID™ Rapid Influenza Test is an easy-to-use, low cost device utilizing high affinity monoclonal antibodies and proprietary lateral flow technology from Nanogen. The technology is capable of detecting and differentiating multiple analytes in the sample. In pre-clinical trials, the assay demonstrated greater than 2 logs improvement in sensitivity over currently available assays.
The same proprietary lateral flow technology and device design will be used in the newly announced development programs. Once development is complete, HX Diagnostics will be granted exclusive commercial license to manufacture and market the resulting products upon regulatory approval.
“The expanded agreement with Nanogen gives us the opportunity to open up our potential market by providing full panels of diagnostics for respiratory illnesses,” said Wendy Benson, president and chief executive officer of HX Diagnostics. “The rapid, accurate diagnosis of these infectious diseases will enable quicker treatment and recovery times for patients.”
The development of the fluID test is supported in part by a 2006 grant from the U.S. Centers for Disease Control and Prevention as part of the U.S. government’s efforts to strengthen its readiness for a potential influenza pandemic.
”Our R&D efforts on the CDC/HX avian influenza project have resulted in a next generation rapid diagnostic technology with breakthrough improvements in sensitivity and precision,” said David Ludvigson, Nanogen’s president and chief operating officer. “Expanding our relationship with HX Diagnostics to include additional respiratory disease diagnostics is a good way for Nanogen to leverage the technology and fulfill our mission of enabling better patient care by bringing to market easier and faster diagnostics.”
About HX Diagnostics, Inc.
HX Diagnostics was founded in 2006 as part of the Kleiner Perkins Caufield & Byers Pandemic Preparedness and BioDefense Initiative with a mission to create improved diagnostics for emerging and infectious diseases. Through its collaborations with leading institutions around the world, HX Diagnostics is creating a diagnostic testing platform that can easily be tailored to enable rapid updates to the device kit as new strains of seasonal or potentially pandemic disease emerge. For more information please visit www.hxdiagnostics.com.
About Nanogen, Inc.
Nanogen, Inc., develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company's products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen's website at www.nanogen.com.
Institutionelle gehen auch langsam wieder mit kleinen Positionen rein!
http://www.mffais.com/ngen.html
habe mir gestern ne kleine Startposition zugelegt!
gruss Macos
Nanogen Partners with Menarini to Capture European Molecular Diagnostics Market
Nov 7, 2008
SAN DIEGO (November 7, 2008) – Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, has entered into an agreement with A. Menarini Diagnostics S.r.l., a division of The Menarini Group, the leading Italian pharmaceutical and diagnostics group, to commercialize CE marked IVD infectious disease kits based on Nanogen’s proprietary MGB technology.
The arrangement combines Nanogen’s strength in real-time PCR IVD product development with Menarini’s significant market presence in the major EU countries and their rapidly expanding reach into the developing Eastern European markets. Under the terms of the agreement the kits will be manufactured by Nanogen and branded as Menarini products. The first products are expected to be introduced to the market in 2009 and will target infectious disease diagnostics.
“Molecular diagnostics is a high growth segment of the global IVD market and real-time PCR has become a gold standard diagnostic technology,” said Howard Birndorf, CEO of Nanogen. “We are pleased to have a partner like Menarini that can help bring our innovative technology to the $1 billion European market. We believe our strong technology and product capabilities together with Menarini’s local sales strength will open a new market and revenue stream for Nanogen and will make a highly competitive offering in Europe.”
About Nanogen, Inc.
Nanogen provides innovative, high quality diagnostic products to clinicians, physicians and researchers worldwide, making it easier to predict, diagnose and, ultimately, help treat disease in a timely fashion. The company's products include molecular diagnostic kits and reagents and kits for rapid, point-of-care diagnostic tests. Nanogen has pioneered research in areas involving nanotechnology, biomarkers, and molecular biology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
About Menarini
Menarini is a leading pharmaceutical company formed over a century ago (1886) with a consolidated turnover above €2.5 billion. Today, the Menarini Group has many licensing partners for the European market and an excellent reputation as an effective and efficient partner, both in the development of new products and new scientific information. Additional information is available on the company's website: www.menarini.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Nov 7, 2008
SAN DIEGO (November 7, 2008) – Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, has entered into an agreement with A. Menarini Diagnostics S.r.l., a division of The Menarini Group, the leading Italian pharmaceutical and diagnostics group, to commercialize CE marked IVD infectious disease kits based on Nanogen’s proprietary MGB technology.
The arrangement combines Nanogen’s strength in real-time PCR IVD product development with Menarini’s significant market presence in the major EU countries and their rapidly expanding reach into the developing Eastern European markets. Under the terms of the agreement the kits will be manufactured by Nanogen and branded as Menarini products. The first products are expected to be introduced to the market in 2009 and will target infectious disease diagnostics.
“Molecular diagnostics is a high growth segment of the global IVD market and real-time PCR has become a gold standard diagnostic technology,” said Howard Birndorf, CEO of Nanogen. “We are pleased to have a partner like Menarini that can help bring our innovative technology to the $1 billion European market. We believe our strong technology and product capabilities together with Menarini’s local sales strength will open a new market and revenue stream for Nanogen and will make a highly competitive offering in Europe.”
About Nanogen, Inc.
Nanogen provides innovative, high quality diagnostic products to clinicians, physicians and researchers worldwide, making it easier to predict, diagnose and, ultimately, help treat disease in a timely fashion. The company's products include molecular diagnostic kits and reagents and kits for rapid, point-of-care diagnostic tests. Nanogen has pioneered research in areas involving nanotechnology, biomarkers, and molecular biology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
About Menarini
Menarini is a leading pharmaceutical company formed over a century ago (1886) with a consolidated turnover above €2.5 billion. Today, the Menarini Group has many licensing partners for the European market and an excellent reputation as an effective and efficient partner, both in the development of new products and new scientific information. Additional information is available on the company's website: www.menarini.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Nanogen and HandyLab Conclude License and Supply Agreements for Real-Time PCR Diagnostics
Feb 25, 2009
SAN DIEGO (February 25, 2009) – Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, announced today that it has expanded its partnership with HandyLab, Inc. by signing a licensing and supply agreement for use of the company’s proprietary Minor Groove Binder (MGB) Probe technology and synthetic nucleic acid chemistries, including dyes and quenchers, for use in in vitro diagnostic testing. Under the licensing agreement, HandyLab receives a non-exclusive license to market, sell and distribute PCR test kits utilizing Nanogen’s patented technology for use on HandyLab’s Jaguar System and other HandyLab systems. Terms of the agreement include an upfront license fee and a commitment to supply HandyLab with Nanogen’s proprietary PCR products.
“Our proprietary MGB technology continues to be the cornerstone for many real-time PCR assays in the rapidly expanding molecular diagnostics market”, said David Ludvigson, Nanogen’s President and Chief Operating Officer. “HandyLab will use our PCR products together with their automated testing platform to provide a complete testing solution for molecular laboratories.”
“HandyLab is excited to pair our novel Jaguar automated nucleic acid test system with Nanogen’s proven MGB chemistry technology”, said Jeff Williams, President and Chief Executive Officer of HandyLab. “This agreement positions us as a fully integrated company with a unique solution for the molecular diagnostic market.”
This licensing agreement marks the expansion of an already established partnership. In 2008, the U.S. Centers for Disease Control and Prevention (CDC) awarded a $10.4 million, two-year contract to Nanogen for the development of a multi-analyte molecular diagnostic assay for Influenza. The Influenza test is being developed for use with the HandyLab microfluidic real-time PCR Raider instrument.
Nanogen’s MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.
About Nanogen, Inc.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company’s products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com
About HandyLab, Inc.
HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products based on its patented and proprietary microfluidic real-time PCR and nucleic acid extraction technologies. The company’s systems reduce the time, complexity and cost of nucleic acid testing while simultaneously improving the quality of results for infectious disease, genetic and other molecular diagnostic tests. For additional information please visit HandyLab’s website at www.handylab.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements
Feb 25, 2009
SAN DIEGO (February 25, 2009) – Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, announced today that it has expanded its partnership with HandyLab, Inc. by signing a licensing and supply agreement for use of the company’s proprietary Minor Groove Binder (MGB) Probe technology and synthetic nucleic acid chemistries, including dyes and quenchers, for use in in vitro diagnostic testing. Under the licensing agreement, HandyLab receives a non-exclusive license to market, sell and distribute PCR test kits utilizing Nanogen’s patented technology for use on HandyLab’s Jaguar System and other HandyLab systems. Terms of the agreement include an upfront license fee and a commitment to supply HandyLab with Nanogen’s proprietary PCR products.
“Our proprietary MGB technology continues to be the cornerstone for many real-time PCR assays in the rapidly expanding molecular diagnostics market”, said David Ludvigson, Nanogen’s President and Chief Operating Officer. “HandyLab will use our PCR products together with their automated testing platform to provide a complete testing solution for molecular laboratories.”
“HandyLab is excited to pair our novel Jaguar automated nucleic acid test system with Nanogen’s proven MGB chemistry technology”, said Jeff Williams, President and Chief Executive Officer of HandyLab. “This agreement positions us as a fully integrated company with a unique solution for the molecular diagnostic market.”
This licensing agreement marks the expansion of an already established partnership. In 2008, the U.S. Centers for Disease Control and Prevention (CDC) awarded a $10.4 million, two-year contract to Nanogen for the development of a multi-analyte molecular diagnostic assay for Influenza. The Influenza test is being developed for use with the HandyLab microfluidic real-time PCR Raider instrument.
Nanogen’s MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.
About Nanogen, Inc.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company’s products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com
About HandyLab, Inc.
HandyLab is dedicated to the development, manufacture and sale of novel molecular diagnostic products based on its patented and proprietary microfluidic real-time PCR and nucleic acid extraction technologies. The company’s systems reduce the time, complexity and cost of nucleic acid testing while simultaneously improving the quality of results for infectious disease, genetic and other molecular diagnostic tests. For additional information please visit HandyLab’s website at www.handylab.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements
die Technologie scheint sich zu bewähren
Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing
Wednesday March 4, 2009, 8:15 am EST
Yahoo! Buzz Print Related:Nanogen, Inc.
SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular and rapid diagnostic products, announced today that it has signed an end user license agreement (EULA) with Quest Diagnostics for use of the Company’s proprietary MGB Probe technology in human in vitro diagnostic testing. Under the licensing agreement, Quest Diagnostics will have rights to use and sell products and services incorporating the MGB Probe technology. Terms of the EULA include an upfront fee and royalties paid on tests sold using the licensed technology.
“We’re proud that Quest Diagnostics, the world’s leader in diagnostic testing, is using our proprietary minor groove binder (MGB) technology and incorporating it into some of their laboratory developed molecular tests,” said Merl Hoekstra, Nanogen’s Vice President of Corporate and Business Development. “We’re proud of the growing reputation and the expanding base of licensed end users of our technology.”
The Company’s MGB Probe technology is broadly licensed in the research and clinical fields and accounts for a majority of the Company’s revenue today. Nanogen has more than 40 reagent and kit products sold for in vitro diagnostic use under the MGB Alert® and Q-PCR Alert™ brands. End users who use or would like to use our proprietary technology should contact our licensing group to obtain a EULA.
About Nanogen, Inc.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company’s products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
Nanogen Licenses Molecular Technology to Quest Diagnostics for In Vitro Diagnostic Testing
Wednesday March 4, 2009, 8:15 am EST
Yahoo! Buzz Print Related:Nanogen, Inc.
SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular and rapid diagnostic products, announced today that it has signed an end user license agreement (EULA) with Quest Diagnostics for use of the Company’s proprietary MGB Probe technology in human in vitro diagnostic testing. Under the licensing agreement, Quest Diagnostics will have rights to use and sell products and services incorporating the MGB Probe technology. Terms of the EULA include an upfront fee and royalties paid on tests sold using the licensed technology.
“We’re proud that Quest Diagnostics, the world’s leader in diagnostic testing, is using our proprietary minor groove binder (MGB) technology and incorporating it into some of their laboratory developed molecular tests,” said Merl Hoekstra, Nanogen’s Vice President of Corporate and Business Development. “We’re proud of the growing reputation and the expanding base of licensed end users of our technology.”
The Company’s MGB Probe technology is broadly licensed in the research and clinical fields and accounts for a majority of the Company’s revenue today. Nanogen has more than 40 reagent and kit products sold for in vitro diagnostic use under the MGB Alert® and Q-PCR Alert™ brands. End users who use or would like to use our proprietary technology should contact our licensing group to obtain a EULA.
About Nanogen, Inc.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company’s products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
Antwort auf Beitrag Nr.: 36.698.848 von Macos am 04.03.09 15:48:39danke.. hatte die news wo angelesen und dann nich wieder gefunden
bis zum 27 Mai haben sie Zeit um die Aktie zu einem Dollar zurückzuführen, sonnst Delisting?
http://finance.aol.com/company/nanogen-inc/ngen/nas/8-K/0961…
gruss macos
http://finance.aol.com/company/nanogen-inc/ngen/nas/8-K/0961…
gruss macos
Zahlen sind da! Cash riecht noch 1 Quartal, irgendwas muss passieren sonnst droht die insolvenz?
Nanogen Reports 2008 Preliminary Unaudited Fourth Quarter and Full Year Financial Results; Continues Efforts on Strategic Transaction
Mar 6, 2009
SAN DIEGO (March 6, 2009) – Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, today reported its preliminary, unaudited financial results for the quarter and year ended December 31, 2008.
For the full year of 2008, total revenues reached $46.9 million, an increase of 23% from the prior year. Fourth quarter revenues declined from third quarter levels due to delayed recognition of contract revenue, exchange rate impacts and seasonality. Total revenues for the fourth quarter of 2008 were $9.5 million, slightly lower than the $9.8 million recorded in the same period in 2007 and 31% percent lower than the $13.8 million recorded in the third quarter of 2008. Product revenues for the fourth quarter of 2008 decreased by 5% to $5.6 million from $5.9 million in the same period in 2007, and decreased by 28% from the $7.8 million recorded in the third quarter of 2008.
Total costs and expenses, including cost of product sales, declined from the level in both the prior year and prior third quarter. In the fourth quarter of 2008 total costs and expenses were $15.0 million compared to $20.8 million in the fourth quarter of 2007 and $18.0 million in the third quarter of 2008. For the full year of 2008, the total of costs and expenses declined to $70.9 million versus $91.9 million in 2007.
For the quarter ended December 31, 2008, Nanogen reported a net loss of $2.0 million, or $0.02 per share, compared to a net loss of $6.5 million or $0.09 per share for the same quarter in 2007, and a net loss of $6.0 million or $0.08 per share in the third quarter of 2008. For the full year of 2008, the net loss was $38.1 million versus $33.9 million in 2007.
Nanogen's consolidated cash, cash equivalents and short-term investments balance at the end of the fourth quarter of 2008 was approximately $3.1 million.
“Our strategy and related restructuring has clearly improved the performance of our business,” said Howard Birndorf, chairman and chief executive officer. “However, our available cash resources are not adequate to support our 2009 plan and therefore, we are aggressively continuing our efforts with Cowen & Co. to identify and evaluate strategic opportunities for our business. This effort is one of our highest priorities.”
In order to conserve its limited cash resources, the company has deferred the audit of its financial statements for the year ended December 31, 2008. Accordingly, the company does not expect to file its Form 10-K by March 31, 2009, the applicable deadline under the applicable rules of the Securities and Exchange Commission.
About Nanogen, Inc.
Nanogen’s in vitro diagnostic products provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and a line of rapid, point-of-care diagnostic tests. For additional information please visit Nanogen’s website at www.nanogen.com.
Cautionary Statement: This press release contains forward-looking statements based on the company’s current expectations. These forward-looking statements include, without limitation, references to the company’s performance and completion of a strategic transaction. Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event. These factors include, but are not limited to, the company’s available cash resource and ability to pay its trade obligations, the willingness of vendors to continue supplying services and materials to the company, the occurrence of defaults under the company’s convertible notes and other obligations, potential creditors actions against the company, including commencing an insolvency proceeding, ability to maintain its Nasdaq listing, and other risks and uncertainties discussed under the caption “Risk Factors” in the company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
Nanogen Reports 2008 Preliminary Unaudited Fourth Quarter and Full Year Financial Results; Continues Efforts on Strategic Transaction
Mar 6, 2009
SAN DIEGO (March 6, 2009) – Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, today reported its preliminary, unaudited financial results for the quarter and year ended December 31, 2008.
For the full year of 2008, total revenues reached $46.9 million, an increase of 23% from the prior year. Fourth quarter revenues declined from third quarter levels due to delayed recognition of contract revenue, exchange rate impacts and seasonality. Total revenues for the fourth quarter of 2008 were $9.5 million, slightly lower than the $9.8 million recorded in the same period in 2007 and 31% percent lower than the $13.8 million recorded in the third quarter of 2008. Product revenues for the fourth quarter of 2008 decreased by 5% to $5.6 million from $5.9 million in the same period in 2007, and decreased by 28% from the $7.8 million recorded in the third quarter of 2008.
Total costs and expenses, including cost of product sales, declined from the level in both the prior year and prior third quarter. In the fourth quarter of 2008 total costs and expenses were $15.0 million compared to $20.8 million in the fourth quarter of 2007 and $18.0 million in the third quarter of 2008. For the full year of 2008, the total of costs and expenses declined to $70.9 million versus $91.9 million in 2007.
For the quarter ended December 31, 2008, Nanogen reported a net loss of $2.0 million, or $0.02 per share, compared to a net loss of $6.5 million or $0.09 per share for the same quarter in 2007, and a net loss of $6.0 million or $0.08 per share in the third quarter of 2008. For the full year of 2008, the net loss was $38.1 million versus $33.9 million in 2007.
Nanogen's consolidated cash, cash equivalents and short-term investments balance at the end of the fourth quarter of 2008 was approximately $3.1 million.
“Our strategy and related restructuring has clearly improved the performance of our business,” said Howard Birndorf, chairman and chief executive officer. “However, our available cash resources are not adequate to support our 2009 plan and therefore, we are aggressively continuing our efforts with Cowen & Co. to identify and evaluate strategic opportunities for our business. This effort is one of our highest priorities.”
In order to conserve its limited cash resources, the company has deferred the audit of its financial statements for the year ended December 31, 2008. Accordingly, the company does not expect to file its Form 10-K by March 31, 2009, the applicable deadline under the applicable rules of the Securities and Exchange Commission.
About Nanogen, Inc.
Nanogen’s in vitro diagnostic products provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and a line of rapid, point-of-care diagnostic tests. For additional information please visit Nanogen’s website at www.nanogen.com.
Cautionary Statement: This press release contains forward-looking statements based on the company’s current expectations. These forward-looking statements include, without limitation, references to the company’s performance and completion of a strategic transaction. Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event. These factors include, but are not limited to, the company’s available cash resource and ability to pay its trade obligations, the willingness of vendors to continue supplying services and materials to the company, the occurrence of defaults under the company’s convertible notes and other obligations, potential creditors actions against the company, including commencing an insolvency proceeding, ability to maintain its Nasdaq listing, and other risks and uncertainties discussed under the caption “Risk Factors” in the company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
Antwort auf Beitrag Nr.: 36.727.136 von Macos am 09.03.09 10:12:39
Nanogen Receives NASDAQ Delisting Notice
Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, announced that on March 12, 2009 the company received a Staff Determination letter from NASDAQ (the “Delisting Notice”) indicating that the Company is subject to delisting proceedings due to non-payment of certain outstanding fees as required for continuing listing set forth in NASDAQ’s Marketplace Rule 4310(c)(13). If the Company elects not to appeal the Delisting Notice, the trading of the Company’s common stock will be suspended at the opening of business on March 23, 2009, and a Form25-NSE will be filed with the SEC which will remove the Company’s common stock from listing and registration on The NASDAQ Stock Market. The Company currently does not plan to file an appeal for the Delisting Notice. Nanogen has filed a Form 8-K with the SEC with additional details about the company’s listing status.
About Nanogen, Inc.
Nanogen’s in vitro diagnostic products provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and a line of rapid, point-of-care diagnostic tests. For additional information please visit Nanogen’s website at www.nanogen.com.
Cautionary Statement: This press release contains forward-looking statements based on the company’s current expectations. These forward-looking statements include, without limitation, references to the company’s performance and strategic transactions. Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event. These factors include, but are not limited to, the company’s available cash resource and ability of the company to pay its trade obligations, the willingness of vendor to continue supplying services and materials to the company, the occurrence of defaults under the company’s convertible notes and other obligations, and other risks and uncertainties discussed under the caption “Risk Factors” in the company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.
Nick Venuto
Chief Financial Officer
858-410-4600
Source: Business Wire (March 13, 2009 - 5:20 PM EDT)
News by QuoteMedia
Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, announced that on March 12, 2009 the company received a Staff Determination letter from NASDAQ (the “Delisting Notice”) indicating that the Company is subject to delisting proceedings due to non-payment of certain outstanding fees as required for continuing listing set forth in NASDAQ’s Marketplace Rule 4310(c)(13). If the Company elects not to appeal the Delisting Notice, the trading of the Company’s common stock will be suspended at the opening of business on March 23, 2009, and a Form25-NSE will be filed with the SEC which will remove the Company’s common stock from listing and registration on The NASDAQ Stock Market. The Company currently does not plan to file an appeal for the Delisting Notice. Nanogen has filed a Form 8-K with the SEC with additional details about the company’s listing status.
About Nanogen, Inc.
Nanogen’s in vitro diagnostic products provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and a line of rapid, point-of-care diagnostic tests. For additional information please visit Nanogen’s website at www.nanogen.com.
Cautionary Statement: This press release contains forward-looking statements based on the company’s current expectations. These forward-looking statements include, without limitation, references to the company’s performance and strategic transactions. Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event. These factors include, but are not limited to, the company’s available cash resource and ability of the company to pay its trade obligations, the willingness of vendor to continue supplying services and materials to the company, the occurrence of defaults under the company’s convertible notes and other obligations, and other risks and uncertainties discussed under the caption “Risk Factors” in the company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.
Nick Venuto
Chief Financial Officer
858-410-4600
Source: Business Wire (March 13, 2009 - 5:20 PM EDT)
News by QuoteMedia
Antwort auf Beitrag Nr.: 36.688.093 von Macos am 03.03.09 11:24:41
Ich warte nur mehr darauf, dass ich jetzt die Lichter ausblasen kann.
dg.
Ich warte nur mehr darauf, dass ich jetzt die Lichter ausblasen kann.
dg.
hi@all:
ngen konnte sich sehr lange an der nasdaq halten...nun wohl nicht mehr..was denkt ihr wie es weitergeht? kommt sie dann gleich nach dem 2303 an die OTC (BB)? ich hatte fast schon Hoffnung das Sie die 1$ Marke nochmal erreichen und an der nasdaq bleiben kann aber nun fiel sie ja auf 0.066$
MIND
ngen konnte sich sehr lange an der nasdaq halten...nun wohl nicht mehr..was denkt ihr wie es weitergeht? kommt sie dann gleich nach dem 2303 an die OTC (BB)? ich hatte fast schon Hoffnung das Sie die 1$ Marke nochmal erreichen und an der nasdaq bleiben kann aber nun fiel sie ja auf 0.066$
MIND
nas 10T
H 0.16
L 0.07
Antwort auf Beitrag Nr.: 36.784.342 von dongabor am 17.03.09 16:16:46so schnell werden die Lichter wohl nicht ausgehen?
Umsätze gesteigert und Verluste reduziert. Gibt bestimmt ne kräftige verwässerung an der otc oder ne Übernahme?
abschreiben würde ich sie noch nicht, könnten auch Ausverkaufskurse sein? von den zittrigen in feste Hände?
keiner weiss es. Stoppkurse nicht vergessen. bin für 0,106 wieder raus, kauf war bei 0,135
die Scheisse ist bei pennys, das sie sich schon täglich halbieren können, schrecklich!
gruss macos
Umsätze gesteigert und Verluste reduziert. Gibt bestimmt ne kräftige verwässerung an der otc oder ne Übernahme?
abschreiben würde ich sie noch nicht, könnten auch Ausverkaufskurse sein? von den zittrigen in feste Hände?
keiner weiss es. Stoppkurse nicht vergessen. bin für 0,106 wieder raus, kauf war bei 0,135
die Scheisse ist bei pennys, das sie sich schon täglich halbieren können, schrecklich!
gruss macos
Antwort auf Beitrag Nr.: 36.790.901 von mindgames1001 am 18.03.09 12:08:15
Servus mindgames !
Gerade der Absturz der letzten Woche und das Unterwandern der 0,1
wird mit Sicherheit dafür sorgen, dass NGEN zum rosa Zettelchen
wird.
Ich kenne mich zwar nicht damit aus, wie die genaueren Bedingungen
sind, um dieses zweifelhafte Ziel zu erreichen, doch schwebte ja
das Damoklesschwert schon lange über dem Titel.
Noch besser gesagt: Es steckte ihm schon im Nacken.
Nachträglich halte man sich noch vor Augen:
NGEN w a r mal knapp über 80 USD wert.
Wie gesagt: War mal !
dg.
Servus mindgames !
Gerade der Absturz der letzten Woche und das Unterwandern der 0,1
wird mit Sicherheit dafür sorgen, dass NGEN zum rosa Zettelchen
wird.
Ich kenne mich zwar nicht damit aus, wie die genaueren Bedingungen
sind, um dieses zweifelhafte Ziel zu erreichen, doch schwebte ja
das Damoklesschwert schon lange über dem Titel.
Noch besser gesagt: Es steckte ihm schon im Nacken.
Nachträglich halte man sich noch vor Augen:
NGEN w a r mal knapp über 80 USD wert.
Wie gesagt: War mal !
dg.
Antwort auf Beitrag Nr.: 36.792.292 von Macos am 18.03.09 14:24:54Das sehe ich genau so...
Spekuliere auf eine Übernahme oder Byout!
Mann beachte die neuen Lizenz Abschlüsse der Letzten Monate.
Solange hier in der Liste noch was drin steht und sogar noch welche Eingestiegen sind, Zocke ich ich mit!.
http://www.mffais.com/ngen.html
Spekuliere auf eine Übernahme oder Byout!
Mann beachte die neuen Lizenz Abschlüsse der Letzten Monate.
Solange hier in der Liste noch was drin steht und sogar noch welche Eingestiegen sind, Zocke ich ich mit!.
http://www.mffais.com/ngen.html
Die Schweinegrippe hat vermutlich den Kurs von Nanogen
beflügelt.
Nanogen hat hervorragende Rapid Tests.
beflügelt.
Nanogen hat hervorragende Rapid Tests.
Da hat es die Schweinegrippe auch nicht mehr gebracht.
Insolvenz (Chapter 11) ist angemeldet und man will wohl des Rest der Firma an Elitech verscherbeln.
http://us.rd.yahoo.com/finance/external/reuters/SIG=118cks9u…
Gruß
Tiefstseetaucher
Insolvenz (Chapter 11) ist angemeldet und man will wohl des Rest der Firma an Elitech verscherbeln.
http://us.rd.yahoo.com/finance/external/reuters/SIG=118cks9u…
Gruß
Tiefstseetaucher
Ich überlege gerade, ob ich nicht wieder einsteigen soll!?
Sehr merkwürdig!
Begründung:
- Freiwillig Chapter 11 beantragen.
- Ein Teilbereich wird an Elitech für über 25 Mio. $ verkauft.
- Der Rest soll angeblich bestmöglich versteigert werden.
Fazit:
Sehr schlauer Fuchs (CEO)!
Elitech wird unter Druck gesetzt, um einen höheren
Preis zu erzielen.
Firma wird evtl. weiterbestehen.
Nur meine Meinung!
Herzliche Grüße
diegutefee
Sehr merkwürdig!
Begründung:
- Freiwillig Chapter 11 beantragen.
- Ein Teilbereich wird an Elitech für über 25 Mio. $ verkauft.
- Der Rest soll angeblich bestmöglich versteigert werden.
Fazit:
Sehr schlauer Fuchs (CEO)!
Elitech wird unter Druck gesetzt, um einen höheren
Preis zu erzielen.
Firma wird evtl. weiterbestehen.
Nur meine Meinung!
Herzliche Grüße
diegutefee
Als C 11 Akie wird NGEN morgen auf jeden Fall noch weiter fallen(technisch gesehen). Ohne Chapter11 lag der Kurs bei 0,05. -70% vom letzten Tief sind aber schon fast normal für eine insolvente AG.
0,015-0,02 sind also morgen schon möglich für einen Einstieg.
0,015-0,02 sind also morgen schon möglich für einen Einstieg.
Kann mir jemand kurz berichten was in der Pipeline ist, worauf NGEN spezialisiert ist, um die weiteren Chancen zu verifizieren?
Antwort auf Beitrag Nr.: 37.177.148 von diegutefee am 14.05.09 17:31:59Moin, moin
Sehe ich ähnlich.
Ch11 ist nicht gleich Ch11 ...
In diesem Fall sollte man sich schlau machen!
Sehe ich ähnlich.
Ch11 ist nicht gleich Ch11 ...
In diesem Fall sollte man sich schlau machen!
Nanogen hat noch eine Tochtergesellschaft in Italien.
Diese Firma wird nicht versteigert, weil sie angeblich
profitabel ist.
Meine Meinung:
Nanogen wird weiterhin bestehen bleiben!
Know-how verkaufen und Lizenzgebühren kassieren.
Siehe Lizenzvertrag mit Quest Diagnostics!
Herzliche Grüße
die gute Fee
Diese Firma wird nicht versteigert, weil sie angeblich
profitabel ist.
Meine Meinung:
Nanogen wird weiterhin bestehen bleiben!
Know-how verkaufen und Lizenzgebühren kassieren.
Siehe Lizenzvertrag mit Quest Diagnostics!
Herzliche Grüße
die gute Fee
Antwort auf Beitrag Nr.: 37.186.262 von diegutefee am 15.05.09 17:02:32der Kurs braucht eine gute Fee...
Nanogen Completes Asset Sale
* Press Release
* Source: Nanogen, Inc.
* On Wednesday July 8, 2009, 5:47 pm EDT
Companies: Nanogen, inc.
SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Other OTC: NGEN.PK - News), developer of molecular and rapid diagnostic products, today announced that on July 2, 2009, pursuant to an Asset Purchase Agreement dated May 13, 2009, as amended, Nanogen and its subsidiaries Epoch BioSciences, Inc. and Nanotronics, Inc. completed their previously announced sale of substantially all of their assets to Financière Elitech SAS (“Elitech”) and its designee DxCon, Inc. in a sale conducted under the provisions of Section 363 of the U.S. Bankruptcy Code (the “Bankruptcy Code”) and approved by the United States Bankruptcy Court for the District of Delaware (the “Court”) on June 24, 2009 (the “Section 363 Sale”). The aggregate gross purchase price for the Section 363 Sale is $25,685,000. For more information about the sale and the voluntary petition filed by Nanogen under Chapter 11 of Title 11 of the Bankruptcy Code in the Court (the “Chapter 11 Proceeding”), please see the company’s report on Form 8-K to be filed on or about July 8, 2009.
Related Quotes
Symbol Price Change
NGEN.PK 0.0380 0.0000
Chart for NANOGEN INC
Elitech plans to operate the Nanogen molecular diagnostics business including Nanogen Advance Diagnostics (Italy) and the Bothell, Washington units. DxCon, Inc. will operate the rapid diagnostics business based out of San Diego, California.
On July 6, 2009, Nanogen filed with the Delaware Secretary of State a Certificate of Amendment of Restated Certificate of Incorporation of Nanogen, Inc. amending its Restated Certificate of Incorporation to change its corporate name from “Nanogen, Inc.” to “Ngen, Inc.”.
This sale concludes the disposition of substantially all of the assets of Nanogen and its U.S. subsidiaries. Management of Nanogen believes that there will be no value for common stockholders of Nanogen in the bankruptcy liquidation process. Stockholders of a company in chapter 11 generally receive value only if all claims of its secured and unsecured creditors are fully satisfied. Nanogen believes that the claims of Nanogen’s creditors will not be fully satisfied, even after completion of the Section 363 Sale or future sales of remaining assets, if any, in the liquidation process.
About Nanogen, Inc.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company’s products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
Contact:
Nanogen, Inc.
Nick Venuto, Chief Financial Officer, 858-410-4600
or
Kelly Gann, Marketing Communications, 858-410-4667
kgann@nanogen.com
* Press Release
* Source: Nanogen, Inc.
* On Wednesday July 8, 2009, 5:47 pm EDT
Companies: Nanogen, inc.
SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Other OTC: NGEN.PK - News), developer of molecular and rapid diagnostic products, today announced that on July 2, 2009, pursuant to an Asset Purchase Agreement dated May 13, 2009, as amended, Nanogen and its subsidiaries Epoch BioSciences, Inc. and Nanotronics, Inc. completed their previously announced sale of substantially all of their assets to Financière Elitech SAS (“Elitech”) and its designee DxCon, Inc. in a sale conducted under the provisions of Section 363 of the U.S. Bankruptcy Code (the “Bankruptcy Code”) and approved by the United States Bankruptcy Court for the District of Delaware (the “Court”) on June 24, 2009 (the “Section 363 Sale”). The aggregate gross purchase price for the Section 363 Sale is $25,685,000. For more information about the sale and the voluntary petition filed by Nanogen under Chapter 11 of Title 11 of the Bankruptcy Code in the Court (the “Chapter 11 Proceeding”), please see the company’s report on Form 8-K to be filed on or about July 8, 2009.
Related Quotes
Symbol Price Change
NGEN.PK 0.0380 0.0000
Chart for NANOGEN INC
Elitech plans to operate the Nanogen molecular diagnostics business including Nanogen Advance Diagnostics (Italy) and the Bothell, Washington units. DxCon, Inc. will operate the rapid diagnostics business based out of San Diego, California.
On July 6, 2009, Nanogen filed with the Delaware Secretary of State a Certificate of Amendment of Restated Certificate of Incorporation of Nanogen, Inc. amending its Restated Certificate of Incorporation to change its corporate name from “Nanogen, Inc.” to “Ngen, Inc.”.
This sale concludes the disposition of substantially all of the assets of Nanogen and its U.S. subsidiaries. Management of Nanogen believes that there will be no value for common stockholders of Nanogen in the bankruptcy liquidation process. Stockholders of a company in chapter 11 generally receive value only if all claims of its secured and unsecured creditors are fully satisfied. Nanogen believes that the claims of Nanogen’s creditors will not be fully satisfied, even after completion of the Section 363 Sale or future sales of remaining assets, if any, in the liquidation process.
About Nanogen, Inc.
Nanogen, Inc. develops diagnostic products that enable physicians to deliver improved patient care. Its products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and a range of infectious diseases. The company’s products include molecular diagnostic kits and reagents, and kits for rapid point-of-care testing. Nanogen has pioneered the development of biomarkers, molecular biology technologies and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
Contact:
Nanogen, Inc.
Nick Venuto, Chief Financial Officer, 858-410-4600
or
Kelly Gann, Marketing Communications, 858-410-4667
kgann@nanogen.com
wie sieht es hier eigentlich aus gibt es eine möglichkeit ch11 wiedermal zu verlassen oder haben die keine chance mehr
sollte man auf diesem niveu mal einen einstieg wagen????
Antwort auf Beitrag Nr.: 37.553.584 von rp75 am 11.07.09 10:15:34Guten Morgen
Der Gedanke ist mir auch gekommen!
Aber die Stimmung in USA ist nicht besonders gut darum warte ich noch ein wenig!
Kannst ja hier mal lesen!
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_N/m…
http://finance.yahoo.com/q?s=NGEN.PK
Der Gedanke ist mir auch gekommen!
Aber die Stimmung in USA ist nicht besonders gut darum warte ich noch ein wenig!
Kannst ja hier mal lesen!
http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_N/m…
http://finance.yahoo.com/q?s=NGEN.PK
Hier ist der Chart!
http://stockcharts.com/h-sc/ui?s=NGEN&p=D&yr=0&mn=3&dy=0&id=…
http://stockcharts.com/h-sc/ui?s=NGEN&p=D&yr=0&mn=3&dy=0&id=…
Antwort auf Beitrag Nr.: 37.683.438 von Lucky72 am 31.07.09 07:46:07Was für ein Dummpush läuft denn bei NGEN gerade?
Ist es deshalb?
http://www.pr.com/press-release/174924
Diese britische Firma Nanogen hat allerdings mit NGEN nüscht zu tun...
NGEN-Aktien bleiben so wertlos wie vorher.
Aus dem filing vom 09.07.2009:
Item 8.01 Other Events.
Management of Nanogen believes that there will be no value for common stockholders of Nanogen in the bankruptcy liquidation process. Stockholders of a company in chapter 11 generally receive value only if all claims of its secured and unsecured creditors are fully satisfied. Nanogen believes that the claims of Nanogen\\\'s creditors will not be fully satisfied, even after completion of the
Section 363 Sale or future sales of remaining assets, if any, in the liquidation process.
Ist es deshalb?
http://www.pr.com/press-release/174924
Diese britische Firma Nanogen hat allerdings mit NGEN nüscht zu tun...
NGEN-Aktien bleiben so wertlos wie vorher.
Aus dem filing vom 09.07.2009:
Item 8.01 Other Events.
Management of Nanogen believes that there will be no value for common stockholders of Nanogen in the bankruptcy liquidation process. Stockholders of a company in chapter 11 generally receive value only if all claims of its secured and unsecured creditors are fully satisfied. Nanogen believes that the claims of Nanogen\\\'s creditors will not be fully satisfied, even after completion of the
Section 363 Sale or future sales of remaining assets, if any, in the liquidation process.
Antwort auf Beitrag Nr.: 37.884.880 von Hypefighter am 31.08.09 13:17:44
Hat jemand eine Ahnung wie es mit den Aktien eigentlich jetzt weitergeht?? Weil wirklich schlau wird man aus den SEC-Fill's auch nicht gerade nicht.
Und ausgebucht wurden sie mir eigentlich auch noch nicht.
Bleiben die weiter bestehen unter NGEN?? Oder werden sie einfach aufgelöst?? Oder werden sie mitübernommen von der neuen Firma??
Vielleicht hat jemand Möglichkeiten mehr zu erfahren bzw. aus den SEC's rauszulesen.
Danke und weiter versuchen zu bleiben.
Hat jemand eine Ahnung wie es mit den Aktien eigentlich jetzt weitergeht?? Weil wirklich schlau wird man aus den SEC-Fill's auch nicht gerade nicht.
Und ausgebucht wurden sie mir eigentlich auch noch nicht.
Bleiben die weiter bestehen unter NGEN?? Oder werden sie einfach aufgelöst?? Oder werden sie mitübernommen von der neuen Firma??
Vielleicht hat jemand Möglichkeiten mehr zu erfahren bzw. aus den SEC's rauszulesen.
Danke und weiter versuchen
zu bleiben. 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,41 | |
| +1,05 | |
| -0,07 | |
| -0,05 | |
| +2,19 | |
| -0,61 | |
| 0,00 | |
| +0,17 | |
| 0,00 | |
| +1,21 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 203 | ||
| 92 | ||
| 70 | ||
| 56 | ||
| 55 | ||
| 45 | ||
| 45 | ||
| 40 | ||
| 33 | ||
| 27 |
